Results 201 to 210 of about 51,949 (245)
Some of the next articles are maybe not open access.
Intravenous Thrombolysis or Medical Management for Minor Strokes
Thrombosis and Haemostasis, 2023Objective To evaluate the outcomes of acute ischemic stroke patients with minor deficits treated with either intravenous thrombolysis (IVT) or routine medical management (MM).Methods The study included patients with acute ischemic stroke and National Institutes of Health Stroke Scale (NIHSS) scores of 5 or less who were treated with IVT within 4.5 ...
Wen-Jun, Tu +5 more
openaire +2 more sources
Coronary Thrombolysis with Intravenous Streptokinase
Cardiology Clinics, 1987Coronary thrombolysis can be achieved with several lytic agents administered via the intravenous or intracoronary routes. Streptokinase, when administered intravenously, produces coronary thrombolysis in from 34 to 75 per cent of patients. Intravenous administration has the advantage of rapid administration without the risks or delays inherent in the ...
openaire +2 more sources
Intravenous Thrombolysis for Acute Ischemic Stroke
Continuum, 2023This article reviews the history of IV thrombolysis, its current indications and implementation, the duality of the "time is brain" versus "tissue clock" approaches, the impact of endovascular thrombectomy on IV thrombolysis, the emergence of tenecteplase, and future research directions.The growing use of factor Xa inhibitors has increasingly caused ...
openaire +2 more sources
2010
This chapter will review the basic mechanisms of clot formation (thrombosis) and dissolution (thrombolysis or fibrinolysis), the mechanisms of the major drug classes used in the treatment, and the results from major clinical trials. This chapter will also present evidence-based recommendations and protocols for applying thrombolytic therapy to ...
Raul Nogueira, Lee H. Schwamm
openaire +1 more source
This chapter will review the basic mechanisms of clot formation (thrombosis) and dissolution (thrombolysis or fibrinolysis), the mechanisms of the major drug classes used in the treatment, and the results from major clinical trials. This chapter will also present evidence-based recommendations and protocols for applying thrombolytic therapy to ...
Raul Nogueira, Lee H. Schwamm
openaire +1 more source
Intravenous thrombolysis for stroke
BMJ, 2010Elderly patients should not be excluded solely on the basis of age Intravenous thrombolytic treatment for acute ischaemic stroke is controversial in patients over 80 years, mainly because they have been excluded from or under-represented in the large scale randomised controlled trials of such treatment.1 2 3 In the linked study (doi:10.1136/bmj.c6046),
openaire +1 more source
Intravenous Thrombolysis and Coronary Revascularization Rates
JAMA: The Journal of the American Medical Association, 1991To the Editor.— The impact of intravenous thrombolysis on the rates of short-term interventional procedures (cardiac catheterization, angioplasty, and bypass surgery) was addressed recently by Naylor and Jaglal 1 and, in an accompanying editorial, by Schlant.
openaire +2 more sources
Off‐label intravenous thrombolysis in acute stroke
European Journal of Neurology, 2011Background and purpose: Therapy for stroke with intravenous tissue plasminogen activator (IV‐tPA) is hampered by tight licensing restrictions; some of them have been discussed in recent literature. We assessed the safety and effectiveness of off‐label IV‐tPA in the clinical settings.Methods: Retrospective analysis of all the patients treated with IV ...
M, Guillan +9 more
openaire +2 more sources
Intravenous Thrombolysis for Acute Ischemic Stroke
Journal of Vascular and Interventional Radiology, 2004Intravenous recombinant tissue-type plasminogen activator (rtPA, alteplase) is the only drug approved for the treatment of acute ischemic stroke. It should be administered within 3 hours of stroke. There is additional evidence, however, that administration at later times, by means of other methods, is effective.
openaire +2 more sources
Intravenous Thrombolysis for Stroke Patients with G6PD Deficiency
Journal of Stroke and Cerebrovascular Diseases, 2018No reports regarding the safety of thrombolysis in acute stroke patients with a G6PD deficiency have been published to date. Here we aimed to evaluate the safety of intravenous thrombolysis for G6PD-deficient stroke patients.We enrolled each patient with acute ischemic stroke who arrived in our stroke unit within the therapeutic window and received ...
Xiaoyan, Wu +7 more
openaire +2 more sources
Intravenous Thrombolysis and Anti-thrombotics
2016Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) has revolutionized acute ischemic stroke care in the last two decades. The NINDS stroke study was pivotal in this transformation and conclusively demonstrated meaningful clinical improvement when IV rtPA is administered in the first 3 h of symptom onset.
Mahesh P. Kate +2 more
openaire +1 more source